Physician profile
Charles A Parent
NPI 1619909249
$8,637.54
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,814 · 2020: $2,276 · 2021: $3,496 · 2022: $50.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,407.90 | 2019-2021 | |
| Pfizer INC. | $924.82 | 2019-2021 | |
| Allergan, INC. | $766.42 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $624.40 | 2019-2021 | |
| Abbvie INC. | $620.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $609.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $537.24 | 2019-2021 | |
| Novo Nordisk INC | $526.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $516.17 | 2019-2021 | |
| Lilly USA, LLC | $317.57 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $231.99 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $209.94 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $150.52 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $148.85 | 2019-2021 | |
| Astellas Pharma US INC | $136.99 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $121.80 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $84.62 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $80.07 | 2020-2021 | |
| Radius Health, INC. | $71.95 | 2019 | |
| Amgen INC. | $68.64 | 2019-2020 | |
| Amarin Pharma, INC. | $62.63 | 2020-2021 | |
| Mylan Specialty L.P. | $51.02 | 2020-2021 | |
| Shire North American Group INC | $48.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $46.88 | 2021 | |
| Esperion Therapeutics, INC. | $42.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $39.02 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $36.07 | 2021 | |
| Neurocrine Biosciences, INC. | $25.68 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.48 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.71 | 2021 | |
| Smith+Nephew, INC. | $11.36 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Parent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.